Kinaxo Biotechnologies will apply its Phosphoscout phosphoproteomics technology to support targeted treatment approaches currently under development at Roche Diagnostics in Penzberg, Germany.
Financial details of the agreement were not disclosed.
Kinaxo's phosphoproteomics platform enables the identification of regulated protein phosphorylation sites in response to therapeutic antibody or kinase inhibitor treatment.
Using quantitative mass spectrometry, up to 15,000 phosphorylation sites can be monitored in a single experiment, facilitating the analysis of the phosphoproteome in patient samples, animal models and cell culture on a global scale.
Unlike immunoassays, Phosphoscout does not require antibodies for detection, thus enabling unbiased, comprehensive phosphoproteome analyses across entire signalling pathways.
This positions Phosphoscout as an upcoming technology for drug mode-of-action analysis and the stratification of cancer patients receiving targeted therapies, according to the company.
